Research Project

Project Title:

A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants Who Have Thrombotic Microangiopathy Associated With a Trigger. ALXN1210-TMA-315

Project Type:

Clinical Trial, Enrolment ongoing

Disease group(s):

Thrombotic microangiopathies

Project Summary:

This study will investigate the efficacy and safety of ravulizumab compared to placebo in adult participants with thrombotic microangiopathy (TMA) associated with a trigger. Participants will be randomized to receive either ravulizumab plus best supportive care or placebo plus best supportive care. The treatment period is 26 weeks followed by a 26-week off-treatment follow-up period.

Lead principal investigator(s):

Piero Ruggenenti, Bergamo


Laura Cappelletti, Bergamo

Project Period:

07/2021   -   06/2024


« Back to research page